Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AD-E6E7 + MG1-E6E7 + atezolizumab
- Development stage
- Unknown
- Lead developer
- Turnstone Biologics
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Intramuscular, Intratumoral
01
Overview
AD-E6E7 + MG1-E6E7 + atezolizumab is an investigational combination immunotherapy targeting human papillomavirus (HPV)-associated cancers, currently under clinical development. - **AD-E6E7** is an adenovirus-based vaccine expressing mutant HPV E6 and E7 antigens engineered to abrogate oncogenic activity while retaining immunogenicity. - **MG1-E6E7** is an oncolytic Maraba virus engineered to express the same mutant HPV E6 and E7 antigens, designed to induce tumor cell lysis and enhance anti-tumor immune responses through virolytic activity and antigen presentation. - **Atezolizumab** is a humanized monoclonal antibody that blocks programmed death-ligand 1 (PD-L1), thereby releasing inhibition of anti-tumor T-cell activity and reinvigorating immune responses[2][4][6]. The regimen is designed with sequential priming and boosting using viral vectors, followed by checkpoint inhibition to maximize CD8+ T cell responses against HPV-induced malignancies and overcome tumor immune evasion[1][3][5].
- Other names
- Ad/MG1-E6E7 + atezolizumab
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on AD-E6E7 + MG1-E6E7 + atezolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AD-E6E7 + MG1-E6E7 + atezolizumab.